CN1149193C - 取代的三环化合物 - Google Patents

取代的三环化合物 Download PDF

Info

Publication number
CN1149193C
CN1149193C CNB991079574A CN99107957A CN1149193C CN 1149193 C CN1149193 C CN 1149193C CN B991079574 A CNB991079574 A CN B991079574A CN 99107957 A CN99107957 A CN 99107957A CN 1149193 C CN1149193 C CN 1149193C
Authority
CN
China
Prior art keywords
methyl
carbazole
formamyl
ethoxyacetic acid
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB991079574A
Other languages
English (en)
Chinese (zh)
Other versions
CN1253948A (zh
Inventor
B��A������ɭ
B·A·安德森
N·J·巴奇
����˹�ٰ�������
J·A·巴斯蒂安
N·K·哈恩
R·W·哈珀
G·A·海特
M·D·金尼克
H·S·林
¡
R·J·隆查里奇
J·M·麦吉尔三世
E·D·米赫利奇
��Ī������
小J·M·莫林
M·L·菲利浦斯
M·E·里彻特
D·J·萨尔
Фү��
J·S·肖耶尔
��лά��
R·W·谢维茨
�����շ�������˹��
R·T·瓦斯勒夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN1253948A publication Critical patent/CN1253948A/zh
Application granted granted Critical
Publication of CN1149193C publication Critical patent/CN1149193C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNB991079574A 1998-04-17 1999-04-16 取代的三环化合物 Expired - Fee Related CN1149193C (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6232898A 1998-04-17 1998-04-17
US09/062,328 1998-04-17
US09/062328 1998-04-17

Publications (2)

Publication Number Publication Date
CN1253948A CN1253948A (zh) 2000-05-24
CN1149193C true CN1149193C (zh) 2004-05-12

Family

ID=22041763

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB991079574A Expired - Fee Related CN1149193C (zh) 1998-04-17 1999-04-16 取代的三环化合物

Country Status (30)

Country Link
EP (2) EP0952149B1 (enExample)
JP (2) JPH11322713A (enExample)
KR (2) KR100586761B1 (enExample)
CN (1) CN1149193C (enExample)
AR (2) AR018186A1 (enExample)
AT (2) ATE268756T1 (enExample)
AU (2) AU753547B2 (enExample)
BR (2) BR9902365A (enExample)
CA (2) CA2269262A1 (enExample)
CO (2) CO5011054A1 (enExample)
CZ (2) CZ137099A3 (enExample)
DE (2) DE69917833T2 (enExample)
DK (1) DK0950657T3 (enExample)
DZ (1) DZ2769A1 (enExample)
EA (2) EA002347B1 (enExample)
ES (2) ES2222663T3 (enExample)
HU (2) HUP9901221A3 (enExample)
ID (2) ID23761A (enExample)
IL (2) IL129485A0 (enExample)
NO (2) NO312240B1 (enExample)
NZ (3) NZ507564A (enExample)
PE (2) PE20000432A1 (enExample)
PL (2) PL332565A1 (enExample)
PT (1) PT950657E (enExample)
SG (2) SG81977A1 (enExample)
SI (1) SI0950657T1 (enExample)
TR (2) TR199900843A2 (enExample)
TW (1) TWI238160B (enExample)
YU (2) YU18999A (enExample)
ZA (2) ZA992772B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610728B2 (en) * 1997-08-28 2003-08-26 Eli Lilly And Company Method for treatment of non-rheumatoid arthritis
DZ2769A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.
CA2358492A1 (en) * 1998-12-21 2000-06-29 Eli Lilly And Company Combination therapy for the treatment of sepsis
DE60032774D1 (de) * 1999-07-19 2007-02-15 Lilly Co Eli Spla2 inhibitoren
US6706752B1 (en) 1999-07-19 2004-03-16 Eli Lilly And Company sPLA2 inhibitors
DE60130891T2 (de) * 2000-06-29 2008-07-17 Anthera Pharmaceuticals Inc., San Mateo Heilmittel für krebs
WO2002000256A1 (fr) * 2000-06-29 2002-01-03 Shionogi & Co., Ltd. Remedes contre la cirrhose
WO2002000257A1 (en) * 2000-06-29 2002-01-03 Shionogi & Co., Ltd. Remedies for alzheimer's disease
CN1450893A (zh) * 2000-07-14 2003-10-22 伊莱利利公司 治疗脓毒症的方法
AU2002239263A1 (en) 2000-12-18 2002-07-01 Eli Lilly And Company Tetracyclic carbazole derivates and their use as spla2 inhibitors
DE60218155D1 (de) 2001-03-28 2007-03-29 Lilly Co Eli Substituierte carbazole als inhibitoren von spla2
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
DE10249055A1 (de) 2002-10-22 2004-05-06 Bayer Cropscience Ag 2-Phenyl-2-substituierte-1,3-diketone
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
EP1988098A1 (en) * 2007-04-27 2008-11-05 AEterna Zentaris GmbH Novel Tetrahydrocarbazole Derivatives as Ligands of G-protein Coupled Receptors
WO2009119534A1 (ja) 2008-03-26 2009-10-01 第一三共株式会社 新規テトラヒドロイソキノリン誘導体
AU2009233711B2 (en) 2008-04-09 2015-02-12 Infinity Pharmaceuticals, Inc Inhibitors of fatty acid amide hydrolase
US8580795B2 (en) 2009-01-22 2013-11-12 Orchid Chemicals & Pharmaceuticals Limited Heterocyclic compounds as phosphodiesterase inhibitors
WO2010118155A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
WO2010118159A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
BR112012019120A2 (pt) 2010-02-03 2016-06-28 Infinity Pharmaceuticais Inc forma sólida, composição farmacêutica, método de preparação do composto 1, método de tratamento de uma condição mediada por faah
AR088377A1 (es) 2011-10-20 2014-05-28 Siena Biotech Spa Proceso para la preparacion de 6-cloro-2,3,4,9-tetrahidro-1h-carbazol-1-carboxamida y compuestos intermedios de esta
CN102816107B (zh) * 2012-08-20 2015-06-03 东南大学 咔唑衍生物及其制备方法与用途
WO2014083163A1 (en) 2012-11-30 2014-06-05 Ge Healthcare Limited Zinc halide mediated cyclization process leading to tricyclic indoles
RU2015118217A (ru) 2012-11-30 2017-01-11 ДжиИ ХЕЛТКЕР ЛИМИТЕД Способ кристаллизации трициклических индольных производных
WO2016116527A1 (de) * 2015-01-20 2016-07-28 Cynora Gmbh Organische moleküle, insbesondere zur verwendung in optoelektronischen bauelementen
CN108707104A (zh) * 2018-08-07 2018-10-26 北京恒信卓元科技有限公司 2-氯-1h-咔唑-1,4(9h)-二酮的合成方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3579534A (en) * 1969-05-09 1971-05-18 American Cyanamid Co Tetrahydrocarbazolecarboxylates
US3979391A (en) * 1972-11-22 1976-09-07 Sterling Drug Inc. 1,2,3,4-Tetrahydrocarbazoles
US3939177A (en) * 1972-11-22 1976-02-17 Sterling Drug Inc. 4-Aminomethyl-9-benzyl-1,2,3,4-tetrahydrocarbazoles
PT95692A (pt) * 1989-10-27 1991-09-13 American Home Prod Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase
US5420289A (en) * 1989-10-27 1995-05-30 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
JPH06509087A (ja) * 1991-07-05 1994-10-13 メルク　シヤープ　エンド　ドーム　リミテツド 芳香族化合物、それらを含む医薬組成物、及び治療におけるそれらの使用
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
EP0749962B1 (en) * 1995-06-23 2000-11-02 Eli Lilly And Company 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta(7,6-B)indoles
DE69614232T2 (de) * 1995-12-13 2002-01-10 Eli Lilly And Co., Indianapolis Naphthyl-Acetamide als sPLA2-Inhibitoren
KR20000049210A (ko) * 1996-10-30 2000-07-25 피터 지. 스트링거 치환된 트리시클릭류
AU9664198A (en) * 1997-09-26 1999-04-23 Eli Lilly And Company Method for the treatment of cystic fibrosis
JP2001522884A (ja) * 1997-11-14 2001-11-20 イーライ・リリー・アンド・カンパニー アルツハイマー病の処置方法
DZ2769A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.

Also Published As

Publication number Publication date
PE20000476A1 (es) 2000-06-02
EP0952149B1 (en) 2004-06-09
DE69918590D1 (de) 2004-08-19
NO314400B1 (no) 2003-03-17
NZ335251A (en) 2000-11-24
ES2222663T3 (es) 2005-02-01
YU18999A (sh) 2002-08-12
CO5011054A1 (es) 2001-02-28
NZ335253A (en) 2000-11-24
BR9902365A (pt) 2001-04-24
TR199900843A2 (xx) 2000-02-21
NZ507564A (en) 2002-10-25
AU753436B2 (en) 2002-10-17
ES2226286T3 (es) 2005-03-16
EP0950657A2 (en) 1999-10-20
AR018186A1 (es) 2001-10-31
HU9901220D0 (en) 1999-06-28
HUP9901221A3 (en) 2001-11-28
ATE271037T1 (de) 2004-07-15
AU753547B2 (en) 2002-10-24
CO5031247A1 (es) 2001-04-27
TWI238160B (en) 2005-08-21
EA199900301A3 (ru) 2000-04-24
CZ137099A3 (cs) 1999-11-17
PL332566A1 (en) 1999-10-25
EA199900301A2 (ru) 1999-10-28
HUP9901220A3 (en) 2001-11-28
NO312240B1 (no) 2002-04-15
DZ2769A1 (fr) 2003-12-01
HU9901221D0 (en) 1999-06-28
ZA992771B (en) 2002-04-18
ID23287A (id) 2000-04-05
JP4435330B2 (ja) 2010-03-17
DK0950657T3 (da) 2004-11-22
PE20000432A1 (es) 2000-05-23
DE69917833D1 (de) 2004-07-15
AU2381799A (en) 1999-10-28
NO991821L (no) 1999-10-18
TR199900853A3 (tr) 1999-11-22
SI0950657T1 (en) 2005-02-28
IL129485A0 (en) 2000-02-29
ZA992772B (en) 2002-07-16
PL332565A1 (en) 1999-10-25
CA2269262A1 (en) 1999-10-17
SG81976A1 (en) 2001-07-24
KR19990083233A (ko) 1999-11-25
HU9901221A (hu) 2000-04-28
BR9901279A (pt) 2000-05-02
JPH11322713A (ja) 1999-11-24
KR100586761B1 (ko) 2006-06-08
TR199900853A2 (xx) 1999-11-22
NO991822D0 (no) 1999-04-16
EA002816B1 (ru) 2002-10-31
CN1253948A (zh) 2000-05-24
IL129483A0 (en) 2000-02-29
AR018593A1 (es) 2001-11-28
DE69918590T2 (de) 2005-07-21
EP0950657A3 (en) 2001-08-16
CZ136999A3 (cs) 1999-11-17
JP2000026416A (ja) 2000-01-25
DE69917833T2 (de) 2005-07-14
PT950657E (pt) 2004-11-30
AU2381999A (en) 1999-10-28
CA2269246A1 (en) 1999-10-17
NO991821D0 (no) 1999-04-16
KR19990083232A (ko) 1999-11-25
YU19199A (sh) 2002-08-12
SG81977A1 (en) 2001-07-24
CA2269246C (en) 2009-08-25
EA199900303A2 (ru) 1999-10-28
NO991822L (no) 1999-10-18
EA199900303A3 (ru) 2000-04-24
ATE268756T1 (de) 2004-06-15
EA002347B1 (ru) 2002-04-25
EP0952149A2 (en) 1999-10-27
EP0952149A3 (en) 2001-08-16
HU9901220A (hu) 2000-04-28
EP0950657B1 (en) 2004-07-14
ID23761A (id) 2000-05-11

Similar Documents

Publication Publication Date Title
CN1253948A (zh) 取代的三环化合物
CN1068588C (zh) 磷脂酶a2抑制剂1h－吲哚－3－乙酰胺类化合物
CN1183111C (zh) 环烷并吲哚和环烷并氮杂吲哚衍生物,其制备方法和含有它们的药物组合物
CN1067986C (zh) 1h－吲哚－3－乙酰肼磷脂酶a2抑制剂
CN1233176A (zh) 取代的三环化合物
CN1361100A (zh) 新的杂环衍生物及其医药用途
CN1279023C (zh) 吲哚－3－硫衍生物
CN1104419C (zh) 苯并吖庚因衍生物
CN1067387C (zh) 1,2,3,4－四氢喹喔啉二酮衍生物
CN1085556A (zh) 抗偏头痛的吲哚-3-基烷基哌嗪的4-嘧啶基和吡啶基衍生物
CN1017425B (zh) 制备杂环酰胺衍生物的方法
CN1671659A (zh) 新的取代吲哚
CN1079464A (zh) 治疗包括胆碱能功能降低的病症有价值的吲哚酮和吲哚二酮的衍生物的制备方法
CN1066065A (zh) 杂环取代的苯乙酸衍生物及其制法和药物用途
CN1298404A (zh) 磷脂酶a2的抑制剂
CN1351602A (zh) 新型药物活性化合物
CN1173497A (zh) 含杂环碳酸衍生物
CN1100417A (zh) N-杂芳基-n＇-苯脲衍生物及其生产和应用
CN1106804A (zh) 1-苯碘酰-1，3-二氢-2h-苯并咪唑-2-酮衍生物
CN1158121A (zh) 吲哚嗪sPLA2抑制剂
CN1768036A (zh) 吲哚酮－乙酰胺衍生物,制备它们的方法和它们的用途
CN1235968A (zh) 取代的三环化合物
CN1993344A (zh) 可用作香草素拮抗剂的色酮衍生物
CN1098103A (zh) 新型吡啶酮羧酸衍生物
CN1085901A (zh) 制备含咪唑并哒嗪衍生物的抗肿瘤药物组合物的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20040512

Termination date: 20120416